A First in Human Study of AdAPT-001 in Subjects With Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is the first clinical trial of AdAPT-001 for the treatment of cancer. AdAPT-001 is an
oncolytic virus that is injected directly into the tumor. The purpose of this study is to
find out the highest dose of AdAPT-001 that is safe and tolerable. This is the first step in
studying whether it can be used to treat others with cancer in the future.